Capmatinib

Capmatinib (brand name Tabrecta) is a medication used to treat a type of lung cancer known as non-small cell lung cancer (NSCLC). It is a type of kinase inhibitor, which means it works by blocking the action of certain proteins in the body that are involved in the growth and spread of cancer cells. It is used in combination with other cancer treatments.

Capmatinib: A Targeted Therapy for Non-Small Cell Lung Cancer

Capmatinib, sold under the brand name Tabrecta, is a prescription medication used to treat a specific type of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs).

Here's a breakdown of Capmatinib's key points:

  • What it treats: Capmatinib is specifically for metastatic NSCLC, meaning the cancer has spread to other parts of the body. However, it's only effective if the cancer cells have a specific mutation in the MET gene. Your doctor will test for this mutation before prescribing Capmatinib.
  • How it works: Capmatinib targets the abnormal MET protein, which plays a crucial role in the growth and survival of cancer cells with this specific mutation. By blocking the action of this protein, Capmatinib helps slow down or stop the growth and spread of cancer cells.
  • Dosage and administration: Capmatinib comes as tablets taken by mouth, usually twice daily with or without food. It's crucial to follow your doctor's instructions regarding dosage and duration of treatment.
  • Side effects: Capmatinib can cause various side effects, including peripheral edema (swelling in hands and feet), fatigue, nausea, diarrhea, and dry skin. Some side effects may require dose adjustments or supportive medications. It's important to discuss potential side effects with your doctor and report any concerning symptoms promptly.

Important points to remember:

  • Capmatinib is not a cure for cancer. It aims to control the disease and improve symptoms.
  • Capmatinib is only available with a prescription from a doctor.
  • It's crucial to inform your doctor about all other medications you're taking, including over-the-counter drugs and herbal supplements, as they may interact with Capmatinib.
  • Regular monitoring with your doctor is essential while undergoing treatment with Capmatinib.
Anatomical Therapeutic Chemical Classification
L - Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX Other protein kinase inhibitors
External Links